Catheter Precision Shareholders Approve Reverse Split, Capital Changes

The latest update is out from Catheter Precision ( (VTAK) ).

On April 15, 2026, Catheter Precision held a Special Meeting of stockholders where approximately 49.5% of outstanding common shares were represented. Shareholders approved the issuance of common shares underlying the company’s Series C-1, C-2, C-3, C-4, D, and J convertible preferred stock, as well as additional shares tied to a reduced conversion price on existing Series B preferred stock.

Investors also authorized an amendment to the certificate of incorporation permitting the board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-100, and approved the potential adjournment or postponement of the meeting to further solicit votes on these matters. The approvals collectively give the company greater flexibility to manage its capital structure and address share price and dilution considerations.

Spark’s Take on VTAK Stock

According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.

The score is held down primarily by persistent large losses and significant cash burn relative to revenue, alongside a pronounced downtrend in the stock. The recent financing and liability conversions improve liquidity prospects and provide some offset, but valuation remains unattractive due to ongoing unprofitability and no dividend support.

To see Spark’s full report on VTAK stock, click here.

More about Catheter Precision

Catheter Precision operates in the medical technology sector, focusing on devices and solutions related to catheter-based procedures. The company’s capital structure includes multiple series of convertible preferred stock, reflecting an active use of equity-linked financing instruments in support of its operations and growth plans.

Average Trading Volume: 1,167,815

Technical Sentiment Signal: Sell

Current Market Cap: $3.28M

Find detailed analytics on VTAK stock on TipRanks’ Stock Analysis page.